OIS@AAO 2016 Videos

Aura Biosciences expects to have an active investigational new drug (IND) application for its first-in-class treatment for primary choroidal melanoma early next year and have…

CHICAGO—Adverum is a gene therapy company “committed to discovering and developing novel medicines that can offer life-changing benefits to patients living with rare diseases or…

Sensimed’s Triggerfish is the “first ever Food and Drug Administration-approved contact lens sensor,” said David Bailey, chief executive officer. The lens received US approval in…

Small aperture technology is the only corneal-based presbyopia-correcting procedure that does not rely on the use of “plus power” in the cornea to provide near…

The Raindrop Near Vision Inlay for the treatment of presbyopia boasts a 2 mm diameter, 80% water composition, the same refractive index as the natural…

Corneal blindness remains a “significant and growing problem,” said Monty Montoya, chief executive officer, SightLife Surgical. There are more than 10 million corneal blind who…

Osmolarity is the one biophysical measurement that “can reliably diagnose dry eye disease (DED) initially and follow the therapeutic response secondarily, said Chris Geddes, PhD,…

What if there was a therapy that could cut dry eye disease (DED) symptoms in half, improve tear secretion three-fold, and be sustainable for a…

For early medtech players in ophthalmology, making connections for start-up capital can be a challenging task, but at the session “Innovative Financing Options in Ophthalmology”…

Ivantis is developing “the only minimally invasive microstent for glaucoma that dilates and reconstructs the primary outflow path of the eye,” said president and chief…

Compliance with topical medication drops to manage glaucoma “is horrid,” said Benjamin Yerxa, PhD, co-founder and president, Envisia Therapeutics. Poor compliance results in disease progression,…

The Evolute Punctal Plug Delivery System provides sustained ocular drug delivery that “is as good or better than what’s out there,” said Bob Butchofsky, Mati…